Critical Reviews in Oncology / Hematology
Volume 78, Issue 2 , Pages 112-126 , May 2011

Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature

  • K. Kamposioras

      Affiliations

    • Panhellenic Association for Continual Medical Research (PACMeR), Greece
    • Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital Attikon, Greece
    • Corresponding Author InformationCorresponding author at: 32 Thrakis Str., Ag. Paraskevi, P.C. 15341, Athens, Greece. Tel.: +30 6937364244.
    • ,
  • G. Pentheroudakis

      Affiliations

    • Department of Medical Oncology, Ioannina University Hospital, Greece
    • ,
  • D. Pectasides

      Affiliations

    • Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital Attikon, Greece
    • ,
  • N. Pavlidis

      Affiliations

    • Department of Medical Oncology, Ioannina University Hospital, Greece

,Accepted 22 April 2010.

References 

  1. Lasithiotakis KG, Leiter U, Gorkievicz R, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer. 2006 Sep 15;107(6):1331–1339
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58(March–April (2)):71–96
  3. Das Gupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynecol Obstet. 1963;117:341–345
  4. Pack GT, Gerber DM, Scharnagel IM. End results in the treatment of malignant melanoma; a report of 1190 cases. Ann Surg. 1952;136(December (6)):90511
  5. Saleh FH, Crotty KA, Hersey P, et al. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melanA/MART-1. Int J Cancer. 2001;94:551–557
  6. Zorn E, Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol. 1999;29:602–607
  7. Sutherland CM, Chmiel JS, Bieligk S, Henson DE, Winchester DP. Patient characteristics, treatment, and outcome of unknown primary melanoma in the United States for the years 1981 and 1987. Am Surg. 1996;62(May (5)):400–406
  8. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol. 2009;27(July (21)):3489–3495
  9. Wang BY, Lawson W, Robinson RA, Perez-Ordonez B, Brandwein M. Malignant melanomas of the parotid: comparison of survival for patients with metastases from known vs unknown primary tumor sites. Arch Otolaryngol Head Neck Surg. 1999;125(June (6)):635–639
  10. Hopewell S, Clarke M, Lusher A, Lefebvre C, Westby M. A comparison of hand searching versus MEDLINE searching to identify reports of randomized controlled trials. Stat Med. 2002;21:1625–1634
  11. McSwain B, Riddell DH, Richie RE, Crocker EF. Malignant melanoma: report of 203 patients. Ann Surg. 1964;June (159):967–975
  12. Einhorn LH, Burgess MA, Vallejos C, et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 1974;34(August (8)):1995–2004
  13. Baab GH, McBride CM. Malignant melanoma: the patient with an unknown site of primary origin. Arch Surg. 1975;110:896–900
  14. Conley J, Hamaker RC. Melanoma of the head and neck. Laryngoscope. 1977;87(May (5 Pt 1)):460–464
  15. Milton GW, Shaw HM, McCarthy WH. Occult primary malignant melanoma: factors influencing survival. Br J Surg. 1977;64:805–808
  16. Giuliano AE, Moseley HS, Morton DL. Clinical aspects of unknown primary melanoma. Ann Surg. 1981;191:98–104
  17. Lopez R, Holyoke ED, Moore RH. Malignant melanoma with unknown primary site. J Surg Oncol. 1982;19:151–154
  18. Chang P, Knapper WH. Metastatic melanoma of unknown primary. Cancer. 1982;49:1106–1111
  19. Spiro RH, DeRose G, Strong EW. Cervical node metastasis of occult origin. Am J Surg. 1983;146(October (4)):441–446
  20. Reintgen DS, McCarty KS, Woodard B, Cox E, Seigler HF. Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet. 1983;156(March (3)):335–340
  21. Panagopoulos E, Murray D. Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol. 1983;23:8–10
  22. Klausner JM, Guzman M, Inbar M, Rozin RR. Unknown primary melanoma. J Surg Oncol. 1983;24:129–131
  23. Santini H, Byers RM, Wolf PF. Melanoma metastatic to cervical and parotid nodes from an unknown primary site. Am J Surg. 1985;150(October (4)):510–512
  24. Muchmore JH, Krementz ET, Carter RD, Sutherland CM, Mendoza EA. Isolated perfusion of extremities for metastatic melanoma from an unknown primary lesion. South Med J. 1986;79(March (3)):288–290
  25. Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg. 1987;122:1380–1383
  26. Jonk A, Kroon BB, Rumke P, Mooi WJ, Hart AA, van Dongen JA. Lymph node metastasis from melanoma with an unknown primary site. Br J Surg. 1990;77:665–668
  27. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg. 1991;214(November (5)):627–636
  28. Velez A, Walsh D, Karakousis CP. Treatment of unknown primary melanoma. Cancer. 1991;68(December (12)):2579–2581
  29. Norman J, Cruse CW, Wells KE, Saba HI, Reintgen DS. Metastatic melanoma with an unknown primary. Ann Plast Surg. 1992;28:81–84
  30. Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72(November (10)):3091–3098
  31. Balm AJ, Kroon BB, Hilgers FJ, Jonk A, Mooi WJ. Lymph node metastases in the neck and parotid gland from an unknown primary melanoma. Clin Otolaryngol Allied Sci. 1994;19(April (2)):161–165
  32. Nasri S, Namazie A, Dulguerov P, Mickel R. Malignant melanoma of cervical and parotid lymph nodes with an unknown primary site. Laryngoscope. 1994;104(October (10)):1194–1198
  33. Pappo AS, Kuttesch JF, Kaste SC, Parham DM, Rao BN, Pratt CB. Malignant melanocytic lesions of unknown primary site in children and adolescents. Med Pediatr Oncol. 1995;24(May (5)):315–320
  34. Schlagenhauff B, Stroebel W, Ellwanger U, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer. 1997;80:60–65
  35. Anbari KK, Schuchter LM, Bucky LP, et al. Melanoma of unknown primary site. Cancer. 1997;79:1816–1821
  36. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer. 1998;83:1664–1678
  37. Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol. 1998;9:419–422
  38. Strobbe LJ, Jonk A, Hart AA, Nieweg OE, Kroon BB. Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol. 1999;6(April–May (3)):255–262
  39. de Wilt JH, Farmer SE, Scolyer RA, McCaughan BC, Thompson JF. Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour?. Melanoma Res. 2005;15(December (6)):531–537
  40. Katz KA, Jonasch E, Hodi FS, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005;15(February (1)):77–82
  41. Ravdel L, Robinson WA, Lewis K, Gonzalez R. Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006;94(August (2)):101–104
  42. Cormier JN, Xing Y, Feng L, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006;106(May (9)):2012–2020
  43. Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol. 2007;25(April (11)):1363–1368
  44. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol. 2008;26(February (4)):535–541
  45. Bedikian AY, Johnson MM, Warneke CL, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008;26(July (6)):624–633
  46. Kelly J, Redmond HP. Melanoma of unknown origin: a case series. Ir J Med Sci. 2009;[July 29; Epub ahead of print]
  47. Nowecki ZI, Rutkowski P, Daiewirski W, et al. Melanoma without detectable primary site with metastases to lymph nodes. Ann Surg Oncol. 2009;16(Suppl. 1):10;[abstract 26]
  48. Smith JL, Stehlin JS. Spontaneous regression of primary malignant melanomas with regional metastases. Cancer. 1965;18(November (11)):1399–1415
  49. Ridolfi RL, Rosen PP, Thaler H. Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer. 1977;39:164–171
  50. Shenoy BV, Fort L, Benjamin SP. Malignant melanoma primary in lymph node: the case of the missing link. Am J Surg Pathol. 1987;11:140–146
  51. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology. 1992;20:315–322
  52. Maurer H, McIntyre OR, Rueckert F. Spontaneous regression of malignant melanoma: pathologic and immunologic study in a ten year survivor. Am J Surg. 1974;127:397–403
  53. Tefany FJ, Barnetson RS, Halliday GM, et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol. 1991;97:197–202
  54. Saleh FH, Crotty KA, Hersey P, et al. Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens. J Pathol. 2003;200:383–395
  55. Clemente CG, Mihm MC, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303–1310
  56. Haanen JB, Baars A, Gomez R, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother. 2006;55:451–458
  57. Morton DL, Malmgren RA, Holmes EC, et al. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968;64:233–240
  58. Lewis MG, Ikonopisov RL, Nairn RC, et al. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. BMJ. 1969;3:547–552
  59. Bodurtha AJ, Chee DO, Laucius JF, et al. Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res. 1975;35:189–193
  60. Canevari S, Fossati G, Della Porta G, et al. Humoral cytotoxicity in melanoma patients and its correlation with the extent and course of the disease. Int J Cancer. 1975;16:722–729
  61. Giuliano AE, Moseley HS, Irie RF, et al. Immunologic aspects of unknown primary melanoma. Surgery. 1980;87:101–105
  62. Litvak DA, Gupta RK, Yee R, et al. Endogenous immune response to early-and intermediate stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J Am Coll Surg. 2004;198:27–35
  63. Hsueh EC, Gupta RK, Yee R, et al. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?. Ann Surg Oncol. 2000;7:232–238
  64. Plaza JA, Torres-Cabala C, Evans H, Diwan HA, Suster S, Prieto VG. Cutaneous metastases of malignant melanoma: a clinicopathologic study of 192 cases with emphasis on the morphologic spectrum. Am J Dermatopathol. 2009;[December 14; Epub ahead of print]
  65. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530–1542
  66. Prichard RS, Dijkstra B, McDermott EW, Hill AD, O’Higgins NJ. The role of molecular staging in malignant melanoma. Eur J Surg Oncol. 2003;29:306–314
  67. Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol. 2009;20(August (Suppl. 6)):vi14–vi21

PII: S1040-8428(10)00092-2

doi: 10.1016/j.critrevonc.2010.04.007

Critical Reviews in Oncology / Hematology
Volume 78, Issue 2 , Pages 112-126 , May 2011

Article Tools